State Ledger
Company profile

Nuvation Bio Inc. CIK 1811063

Ticker
NUVB (NYSE)
Industry
Pharmaceutical Preparations
Headquarters
New York, NY 10036
Fiscal year end
2025 (FY)
Market Data
Close
$4.72
Change
-$0.17
Change %
-3.48%
Volume
456,886

NUVB · trading date Oct 13, 2026 · previous close $4.89 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
$62.90M
Net income
-$204.63M
Total assets
$594.82M
Total liabilities
$289.11M
Stockholders' equity
$305.72M
Cash & equivalents
$164.09M
Operating income
-$213.06M
Operating cash flow
-$173.43M
Capital expenditures
$8.00M

Fiscal year 2025, via 10-K filed 2026-03-02. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
-338.7%
Net margin
-325.3%
Free cash flow
-$181.43M
Free cash flow margin
-288.4%
Liabilities / assets
48.6%
Equity / assets
51.4%
CapEx / revenue
12.7%
Operating cash flow / net income
0.85×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 $62.90M -$204.63M $594.82M $289.11M $305.72M
2024 $7.87M -$567.94M $540.63M $76.84M $463.79M
2023 $0 -$75.80M $621.48M $16.36M $605.12M
2022 — -$104.20M $672.14M $17.07M $655.08M
2021 — -$86.85M $776.15M $30.15M $746.00M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 4
2026-08-21
Financials filed via
Form 10-K
filed 2026-03-02

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
New York, NY 10036
1500 BROADWAY
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:45 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New York — Public Companies